Zymeworks Inc.

ZYME - CIK 0001937653

Market cap$1.85 B

Rank#2155

SEC filings324

Zymeworks Inc. trades as ZYME and has a market capitalization of $1.85 B, making it the #2155 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $105.97M, up 38.9% from the prior year and net income of -$81.13M. This page tracks Zymeworks Inc. through 324 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$105.97MFY 2025

Net income (latest FY)-$81.13MFY 2025

Operating cash flow (latest FY)-$33.01MFY 2025

Total assets (latest FY)$346.53MFY 2025

Net margin-76.6%latest FY

Financial performance

Over the last 5 fiscal years Zymeworks Inc.'s revenue grew from $38.95M to $105.97M, a compound annual growth rate of 22.2%. Net profit margin expanded from -463.5% to -76.6% over the same period - every figure below comes from the company's audited annual filings.

ZYME annual revenueView details

ZYME annual net incomeView details

Key statistics

Market cap: $1.85 B
Share price (derived)market cap / shares outstanding: $25.33
EPS (diluted)FY 2025: $-1.08
Shares outstandingas of 2026-05-06: 0.07B
Total equityas of 2026-03-31: $163.59M
Return on equity: -49.6%
Cash & equivalentsas of 2026-03-31: $244.28M
Stock buybacksFY 2025: $41.70M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-15
New insider ownership	3	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
Major company event	8-K	2026-05-14
Quarterly report	10-Q	2026-05-07
Major company event	8-K	2026-05-07
SCHEDULE 13G	-	2026-04-15
Insider trade	4	2026-04-10

Browse the full filing history (324 filings)

Recent press releases

Zymeworks Announces Participation in Upcoming Investor Conferences2026-05-22
Zymeworks Announces Participation in Upcoming Investor Conferences | Zymeworks Inc.
Zymeworks Appoints Kristin Stafford as Chief Financial Officer2026-05-22
Zymeworks Appoints Kristin Stafford as Chief Financial Officer | Zymeworks Inc.
Zymeworks Announces Participation in Upcoming Investor Conferences2026-05-22
Zymeworks Announces Participation in Upcoming Investor Conferences | Zymeworks Inc.
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock2026-05-22
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock | Zymeworks Inc.
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026 China’s NMPA has 05.07.20262026-05-22
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results | Zymeworks Inc.

Similar companies

The largest companies sharing Zymeworks Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T ZYME vs LLY

JNJJohnson & Johnson$573.98 B ZYME vs JNJ

ABBVAbbVie Inc.$399.47 B ZYME vs ABBV

MRKMerck & Co., Inc.$293.16 B ZYME vs MRK

AZNAstraZeneca PLC$286.27 B ZYME vs AZN

Frequently asked questions

What is Zymeworks Inc.'s market cap?

Zymeworks Inc. (ZYME) has a market capitalization of $1.85 B as of 2026-05-29, ranking #2155 among US-listed companies.

How much revenue does Zymeworks Inc. make?

Zymeworks Inc. reported revenue of $105.97M for fiscal year 2025, an increase of 38.9% year over year.

Is Zymeworks Inc. profitable?

In its latest fiscal year Zymeworks Inc. reported a net loss of $81.13M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.